| Medical and Health Sciences | 2021-2025 | 326 | US 116 | 99.93 |
| Pulmonary and Respiratory Medicine | Lifetime | 144 | US 75 | 99.82 |
| Oncology | Lifetime | 532 | US 293 | 99.03 |
| Cancer Research | Lifetime | 495 | US 259 | 96.92 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 26 | US 10 | 99.89 |
| Oncology | 2021-2025 | 106 | US 46 | 99.37 |
| Cancer Research | 2021-2025 | 37 | US 12 | 98.45 |
| Medical Genetics | 2021-2025 | 261 | US 118 | 85.23 |
| Lung Cancer Treatments and Mutations | Lifetime | 59 | US 34 | 99.80 |
| Cancer Genomics and Diagnostics | Lifetime | 170 | US 106 | 99.61 |
| Lung Cancer Research Studies | Lifetime | 108 | US 60 | 99.48 |
| Colorectal Cancer Treatments and Studies | Lifetime | 170 | US 85 | 99.40 |
| Cancer Mechanisms and Therapy | Lifetime | 135 | US 68 | 98.45 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 282 | US 95 | 98.72 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 712 | US 356 | 98.47 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 369 | US 219 | 97.10 |
| Melanoma and MAPK Pathways | Lifetime | 272 | US 144 | 97.13 |
| HER2/EGFR in Cancer Research | Lifetime | 663 | US 300 | 97.32 |
| Liver physiology and pathology | Lifetime | 662 | US 206 | 95.37 |
| Chromatin Remodeling and Cancer | Lifetime | 276 | US 141 | 93.45 |
| Cancer Genomics and Diagnostics | 2021-2025 | 22 | US 10 | 99.73 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 21 | US 8 | 99.86 |
| Lung Cancer Research Studies | 2021-2025 | 35 | US 15 | 99.40 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 37 | US 14 | 99.36 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 872 | US 322 | 96.61 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 546 | US 177 | 96.03 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 412 | US 185 | 95.84 |
| Melanoma and MAPK Pathways | 2021-2025 | 109 | US 32 | 94.12 |
| HER2/EGFR in Cancer Research | 2021-2025 | 325 | US 116 | 94.72 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 530 | US 100 | 92.17 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 601 | US 140 | 90.14 |
| Cancer Mechanisms and Therapy | 2021-2025 | 283 | US 43 | 86.27 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 167 | US 74 | 84.50 |
| Brain Metastases and Treatment | 2021-2025 | 762 | US 334 | 84.57 |
| Cancer therapeutics and mechanisms | 2021-2025 | 505 | US 112 | 80.92 |
| Cancer-related Molecular Pathways | 2021-2025 | 599 | US 201 | 78.21 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 756 | US 143 | 70.12 |
| Chromatin Remodeling and Cancer | 2021-2025 | 911 | US 355 | 55.24 |
| Protein Tyrosine Phosphatases | 2021-2025 | 630 | US 187 | 48.44 |
| Lymphatic Disorders and Treatments | 2021-2025 | 206 | US 76 | 42.62 |
